FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 299:1151-1155 November 23, 1978 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To evaluate the effectiveness of cyclophosphamide in the treatment of lupus nephritis, we designed a prospective study of patients with diffuse proliferative lupus nephritis. Twenty-six patients received prednisone (average dose, 40 mg per day) and 24 combined prednisone (average dose, 29 mg per day) and cyclophosphamide (average dose, 107 mg per day) for six months. Thereafter, all patients received maintenance doses of prednisone. Most of the patients improved (84 per cent) after six months of initial treatment with either program. Early progression of disease, ending mainly in end-stage renal disease, was equally frequent in the two treatment groups in patients with already advanced disease. In a four-year follow-up study there was a higher incidence (P approximately 0.04) and average rate (P approximately 0.02) of clinical recurrence of nephritis in the group initially given only steroid than in the group initially given both drugs. However, the proportion of patients alive after four years with stable or improved renal function was similar in the two treatment groups.

This article has been cited by other articles:

• Bargman, J. M. (2008). How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant 0: gfn640v1-gfn640 [Full Text]  
• F, L., Y, T., X, P., L, W., H, W., Z, S., H, Z., Z, H. (2008). A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 17: 622-629 [Abstract]  
• Ballardie, F. W. (2007). Quantitative Appraisal of Treatment Options for IgA Nephropathy. J. Am. Soc. Nephrol. 18: 2806-2809 [Abstract] [Full Text]  
• Zhu, B., Chen, N., Lin, Y., Ren, H., Zhang, W., Wang, W., Pan, X., Yu, H. (2007). Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933-1942 [Abstract] [Full Text]  
• Houssiau, F (2007). Thirty years of cyclophosphamide: assessing the evidence. Lupus 16: 212-216 [Abstract]  
• Grootscholten, C., Berden, J. H. M. (2006). Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?. Nephrol Dial Transplant 21: 1465-1469 [Full Text]  
• Fine, D. M. (2005). Pharmacological Therapy of Lupus Nephritis. JAMA 293: 3053-3060 [Abstract] [Full Text]  
• Chan, T M, Tse, K C, Tang, C S., Lai, K N, Li, F K (2005). Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14: 265-272 [Abstract]  
• Chan, T M (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Contreras, G, Tozman, E, Nahar, N., Metz, D. (2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14: s33-s38 [Abstract]  
• Sidiropoulos, P I, Kritikos, H D, Boumpas, D T (2005). Lupus nephritis flares. Lupus 14: 49-52 [Abstract]  
• Houssiau, F A (2005). Cyclophosphamide in lupus nephritis. Lupus 14: 53-58 [Abstract]  
• Chan, T. (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Contreras, G., Tozman, E., Nahar, N., Metz, D. (2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14: s33-s38 [Abstract]  
• Balow, J. E., Austin, H. A. III (2004). Maintenance Therapy for Lupus Nephritis -- Something Old, Something New. NEJM 350: 1044-1046 [Full Text]  
• Mok, C C, Wong, R W S, Lai, K N (2003). Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 62: 799-804 [Abstract] [Full Text]  
• Ramos, M A., Pinera, C., Setien, M A., Buelta, L., de Cos, M A., de Francisco, A.-L. M., Merino, R., Arias, M. (2003). Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZBxNZW)F1 mice. Nephrol Dial Transplant 18: 878-883 [Abstract] [Full Text]  
• MacGowan, J. R., Ellis, S., Griffiths, M., Isenberg, D. A. (2002). Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford) 41: 981-987 [Abstract] [Full Text]  
• Kozdemir, H K., Yucel, A E, Kunefeci, G, Ozdemir, F N, Duran, H (2001). Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 10: 818-820 [Abstract]  
• Adu, D. (2001). The evidence base for the treatment of lupus nephritis in the new millennium. Nephrol Dial Transplant 16: 1536-1538 [Full Text]  
• Takada, K, Illei, G G, Boumpas, D T (2001). Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10: 154-161 [Abstract]  
• Chan, T. M., Li, F. K., Tang, C. S.O., Wong, R. W.S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K.M., Tong, M. K.L., Chan, K. W., Lai, K. N., The Hong Kong#x2013;Guangzhou Nephrology Study Gro, (2000). Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis. NEJM 343: 1156-1162 [Abstract] [Full Text]  
• Falk, R. J. (2000). Treatment of Lupus Nephritis -- A Work in Progress. NEJM 343: 1182-1183 [Full Text]  
• Chan, T M, Li, F K, Hao, W K, Chan, K W, Lui, S L, Tang, S, Lai, K N (1999). Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 8: 545-551 [Abstract]  
• Mittal, G, Balakrishna, C, Mangat, G, Joshi, V R (1999). 'Sustained remission' in a case of SLE following megadose cyclophosphamide. Lupus 8: 77-80 [Abstract]  
• Boumpas, D T, Balow, J E (1998). Outcome criteria for lupus nephritis trials: A critical overview. Lupus 7: 622-629 [Abstract]  
• Dooley, M A, Falk, R J (1998). Immunosuppressive therapy of lupus nephritis. Lupus 7: 630-634 [Abstract]  
• Ponticelli, C, Moroni, G (1998). Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus 7: 635-638 [Abstract]  
• Langford, C. A., Klippel, J. H., Balow, J. E., James, S. P., Sneller, M. C. (1998). Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease: Part 1: Rheumatologic and Renal Diseases. ANN INTERN MED 128: 1021-1028 [Abstract] [Full Text]  
• Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., Steinberg, A. D. (1996). Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis: A Randomized, Controlled Trial. ANN INTERN MED 125: 549-557 [Abstract] [Full Text]  
• Hanly, J.G., Hong, C., Zayed, E., Jones, J.V., Jones, E. (1995). Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 4: 457-463 [Abstract]  
• Boumpas, D. T., Austin, H. A., Fessler, B. J., Balow, J. E., Klippel, J. H., Lockshin, M. D. (1995). Systemic Lupus Erythematosus: Emerging Concepts: Part 1: Renal, Neuropsychiatric, Cardiovascular, Pulmonary, and Hematologic Disease. ANN INTERN MED 122: 940-950 [Abstract] [Full Text]  
• Belmont, H M., Storch, M., Buyon, J., Abramson, S. (1995). New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4: 104-108 [Abstract]